Myostatin and insulin-like growth factor I: potential therapeutic biomarkers for pompe disease.

PLoS One · 2013 · PMC3743802 · PMID 23967261

Europe PMC DOI

hedged sentences

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

bordered on significancep = 0.075so close (0.05 < p ≤ 0.1)

307.9 ng/ml, p = 0.010) and lower myostatin levels that bordered on significance (1.38 ng/ml vs. 3.32 ng/ml, p = 0.075).

also in 114 other papers

borderline significancep = 0.075so close (0.05 < p ≤ 0.1)

307.9 ng/ml, respectively, p = 0.010), in addition to lower myostatin levels with borderline significance (1.38 ng/ml in Pompe disease vs. 3.32 ng/ml in control subjects, p = 0.075).

also in 7,017 other papers

showed a trendno p-value reported

In conclusion, serum IGF-1 levels were significantly lower in Pompe disease patients relative to normal control subjects, and serum myostatin also showed a trend for lower levels.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.